Li Kang Biomedical Co., Ltd. (TPEX:6242)
Taiwan · Delayed Price · Currency is TWD 38.15
0.00 (0.00%)
Jun 15, 2026, 1:30 PM CST
Li Kang Biomedical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 77.56 | 83.82 | 77.02 | 110.99 | 112.09 | 51.44 |
Depreciation & Amortization | 7.61 | 8.79 | 12.43 | 11.74 | 10.99 | 12.89 |
Loss (Gain) From Sale of Investments | 0.79 | 0.46 | -0.28 | -0.9 | 2.2 | 1.75 |
Stock-Based Compensation | - | - | 4.64 | - | - | - |
Other Operating Activities | -4.84 | -4.1 | -29.45 | -5.4 | 13.2 | -8.71 |
Change in Accounts Receivable | -0.01 | 0.18 | -0.25 | 0.92 | -2.15 | -0.59 |
Change in Inventory | -2.48 | -0.7 | -3.66 | -8.79 | -4.25 | 2.64 |
Change in Accounts Payable | -3.83 | -1.07 | 4.57 | -8 | 3.76 | 8.18 |
Change in Other Net Operating Assets | -4.05 | 4.76 | 0.35 | -3.82 | 21.41 | -7.16 |
Operating Cash Flow | 70.56 | 92.15 | 65.38 | 96.74 | 157.24 | 60.45 |
Operating Cash Flow Growth | -3.61% | 40.94% | -32.42% | -38.48% | 160.14% | -25.98% |
Capital Expenditures | -314.35 | -329.38 | -62.75 | -3.26 | -1.16 | -4.25 |
Sale (Purchase) of Intangibles | -0.28 | -0.17 | -1.98 | - | -1.54 | -0.2 |
Investment in Securities | 166.2 | 241.24 | -199.54 | -62.01 | -58.33 | 14.44 |
Other Investing Activities | 3.3 | 4.74 | 6.5 | 3.43 | 1.41 | 2.21 |
Investing Cash Flow | -145.13 | -83.57 | -257.76 | -61.84 | -59.62 | 12.2 |
Short-Term Debt Issued | - | 120 | 24 | 12 | - | - |
Long-Term Debt Issued | - | - | 35 | 35 | - | - |
Total Debt Issued | 134 | 120 | 59 | 47 | - | - |
Short-Term Debt Repaid | - | -50 | -24 | -12 | - | - |
Long-Term Debt Repaid | - | -36.98 | -35 | -43.48 | -33.47 | -7.52 |
Total Debt Repaid | -100.98 | -86.98 | -59 | -55.48 | -33.47 | -7.52 |
Net Debt Issued (Repaid) | 33.02 | 33.02 | - | -8.48 | -33.47 | -7.52 |
Issuance of Common Stock | - | - | 225 | - | - | - |
Common Dividends Paid | -63.61 | -63.61 | -79.52 | -46.62 | -33.3 | -62.16 |
Other Financing Activities | - | - | - | 0.02 | -0.2 | 0.29 |
Financing Cash Flow | -30.6 | -30.6 | 145.48 | -55.07 | -66.97 | -69.39 |
Net Cash Flow | -105.17 | -22.02 | -46.9 | -20.17 | 30.65 | 3.26 |
Free Cash Flow | -243.79 | -237.23 | 2.63 | 93.48 | 156.08 | 56.19 |
Free Cash Flow Growth | - | - | -97.19% | -40.11% | 177.77% | -29.67% |
Free Cash Flow Margin | -42.33% | -40.26% | 0.46% | 14.85% | 22.81% | 14.52% |
Free Cash Flow Per Share | -7.67 | -7.42 | 0.08 | 3.47 | 5.79 | 2.09 |
Cash Interest Paid | 0.37 | 0.37 | 0.25 | 0.62 | 0.32 | 0.42 |
Cash Income Tax Paid | 18.08 | 18.08 | 43.33 | 28.53 | 12.06 | 17.79 |
Levered Free Cash Flow | -295.66 | -256.22 | -13.73 | 70.08 | 127.73 | 40.35 |
Unlevered Free Cash Flow | -295.43 | -255.98 | -13.3 | 70.47 | 127.91 | 40.64 |
Change in Working Capital | -10.37 | 3.17 | 1.02 | -19.69 | 18.76 | 3.07 |